Literature DB >> 28479601

B7-DC (PD-L2) costimulation of CD4+ T-helper 1 response via RGMb.

Xinxin Nie1, Wenni Chen1, Ying Zhu1, Baozhu Huang1, Weiwei Yu1, Zhanshuai Wu1, Sizheng Guo1, Yiping Zhu1, Liqun Luo1, Shengdian Wang2, Lieping Chen3,4.   

Abstract

The role of B7-DC in T-cell responses remains controversial because both coinhibitory and costimulatory functions have been reported in various experimental systems in vitro and in vivo. In addition to interacting with the coinhibitory receptor PD-1, B7-DC has also been shown to bind repulsive guidance molecule b (RGMb). The functional consequences of the B7-DC/RGMb interaction, however, remain unclear. More than a decade ago, we reported that replacement of a murine B7-DC mutant lysine with serine (K113S) at positive 113 resulted in a loss of binding capacity to PD-1. Nevertheless, K113S remained costimulatory for T cells in vitro, implicating a dual functionality for B7-DC in T-cell responses. Here we show that recombinant K113S protein interacts with RGMb with a similar affinity to wild-type B7-DC. More importantly, K113S costimulates CD4+ T-cell responses via RGMb and promotes Th1 polarization. RGMb is expressed on the surface of naive mouse T cells, macrophages, neutrophils and dendritic cells. Finally, K113S/RGMb costimulation suppresses Th2-mediated asthma and ameliorates small airway inflammation and lung pathology in an experimental mouse model. Our findings indicate that RGMb is a costimulatory receptor for B7-DC. These findings from the K113S variant provide not only a possible explanation for the B7-DC-triggered contradictory effects on T-cell responses, but also a novel approach to investigate the B7-DC/PD-1/RGMb axis. Recombinant K113S or its derivatives could potentially be developed as an agonist for RGMb to costimulate the Th1 response without triggering PD-1-mediated T-cell inhibition.

Entities:  

Keywords:  B7-DC; K113S; RGMb; Th1/Th2; asthma

Mesh:

Substances:

Year:  2017        PMID: 28479601      PMCID: PMC6207567          DOI: 10.1038/cmi.2017.17

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  40 in total

Review 1.  The role of Th1/Th2 polarization in mucosal immunity.

Authors:  Markus F Neurath; Susetta Finotto; Laurie H Glimcher
Journal:  Nat Med       Date:  2002-06       Impact factor: 53.440

2.  Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues.

Authors:  Masayoshi Ishida; Yoshiko Iwai; Yoshimasa Tanaka; Taku Okazaki; Gordon J Freeman; Nagahiro Minato; Tasuku Honjo
Journal:  Immunol Lett       Date:  2002-10-21       Impact factor: 3.685

Review 3.  Airway remodeling in asthma.

Authors:  Rabih Halwani; Saleh Al-Muhsen; Qutayba Hamid
Journal:  Curr Opin Pharmacol       Date:  2010-06-28       Impact factor: 5.547

4.  Dragon (repulsive guidance molecule b) inhibits IL-6 expression in macrophages.

Authors:  Yin Xia; Virna Cortez-Retamozo; Vera Niederkofler; Rishard Salie; Shanzhuo Chen; Tarek A Samad; Charles C Hong; Silvia Arber; Jatin M Vyas; Ralph Weissleder; Mikael J Pittet; Herbert Y Lin
Journal:  J Immunol       Date:  2010-12-27       Impact factor: 5.422

Review 5.  The many paths to asthma: phenotype shaped by innate and adaptive immunity.

Authors:  Hye Young Kim; Rosemarie H DeKruyff; Dale T Umetsu
Journal:  Nat Immunol       Date:  2010-06-18       Impact factor: 25.606

6.  Repulsive guidance molecule B (RGMB) plays negative roles in breast cancer by coordinating BMP signaling.

Authors:  Jin Li; Lin Ye; Andrew J Sanders; Wen G Jiang
Journal:  J Cell Biochem       Date:  2012-07       Impact factor: 4.429

7.  Regulation of T cell activation and tolerance by PDL2.

Authors:  Yongliang Zhang; Yeonseok Chung; Caroline Bishop; Betsy Daugherty; Hilary Chute; Paige Holst; Carole Kurahara; Fred Lott; Ning Sun; Andrew A Welcher; Chen Dong
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-24       Impact factor: 11.205

8.  Programmed Death-1 antibody blocks therapeutic effects of T-regulatory cells in cockroach antigen-induced allergic asthma.

Authors:  Halvor S McGee; Hideo Yagita; Zhifei Shao; Devendra K Agrawal
Journal:  Am J Respir Cell Mol Biol       Date:  2009-11-09       Impact factor: 6.914

Review 9.  Th2 cytokines and asthma. Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists.

Authors:  J W Steinke; L Borish
Journal:  Respir Res       Date:  2001-02-19

10.  Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice.

Authors:  S H Gavett; D J O'Hearn; X Li; S K Huang; F D Finkelman; M Wills-Karp
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

View more
  14 in total

1.  Dynamic proteomic change of tumor and immune organs in an immune-competent hepatocellular carcinoma mouse model.

Authors:  Jiaqi Jiao; Linlin Ji; Xianju Li; Zhan Gao; Guangshun Wang; Jun Qin; Yini Wang; Yi Wang
Journal:  Am J Cancer Res       Date:  2022-04-15       Impact factor: 5.942

2.  A checkpoint cliffhanger at the dawn of placental mammals.

Authors:  Michael L Dustin; Ana C Zenclussen
Journal:  J Biol Chem       Date:  2020-04-03       Impact factor: 5.157

3.  PD-L2 Regulates B-1 Cell Antibody Production against Phosphorylcholine through an IL-5-Dependent Mechanism.

Authors:  Jerome T McKay; Marcela A Haro; Christina A Daly; Rama D Yammani; Bing Pang; W Edward Swords; Karen M Haas
Journal:  J Immunol       Date:  2017-08-02       Impact factor: 5.422

Review 4.  Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer.

Authors:  Maarten Versteven; Johan M J Van den Bergh; Elly Marcq; Evelien L J Smits; Viggo F I Van Tendeloo; Willemijn Hobo; Eva Lion
Journal:  Front Immunol       Date:  2018-03-01       Impact factor: 7.561

Review 5.  Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer.

Authors:  Ewelina Grywalska; Marcin Pasiarski; Stanisław Góźdź; Jacek Roliński
Journal:  Onco Targets Ther       Date:  2018-10-04       Impact factor: 4.147

6.  PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor.

Authors:  Zhi-Liang Wang; Guan-Zhang Li; Qiang-Wei Wang; Zhao-Shi Bao; Zheng Wang; Chuan-Bao Zhang; Tao Jiang
Journal:  Oncoimmunology       Date:  2018-11-20       Impact factor: 8.110

7.  PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.

Authors:  Trine Vilsbøll Larsen; Dianna Hussmann; Anders Lade Nielsen
Journal:  Cancer Commun (Lond)       Date:  2019-06-03

8.  Enhanced antitumor immune response in melanoma tumor model by anti-PD-1 small interference RNA encapsulated in nanoliposomes.

Authors:  Mehdi Barati; Farshad Mirzavi; Amin Reza Nikpoor; Mojtaba Sankian; Hasan Namdar Ahmadabad; Anvar Soleimani; Mohammad Mashreghi; Jalil Tavakol Afshar; Mojgan Mohammadi; Mahmoud Reza Jaafari
Journal:  Cancer Gene Ther       Date:  2021-08-02       Impact factor: 5.854

9.  Adaptive selection in the evolution of programmed cell death-1 and its ligands in vertebrates.

Authors:  Hafiz Ishfaq Ahmad; Jiabin Zhou; Muhammad Jamil Ahmad; Gulnaz Afzal; Haiying Jiang; Xiujuan Zhang; Abdelmotaleb A Elokil; Musarrat Abbas Khan; Linmiao Li; Huiming Li; Liu Ping; Jinping Chen
Journal:  Aging (Albany NY)       Date:  2020-02-11       Impact factor: 5.682

Review 10.  Targeting Natural Killer Cells for Tumor Immunotherapy.

Authors:  Cai Zhang; Yuan Hu; Chongdeng Shi
Journal:  Front Immunol       Date:  2020-02-19       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.